Lynx Biosciences

Lynx Biosciences is a San Diego-based biotech company pioneering a data-first, multi-omic platform for drug discovery in immuno-oncology. The company combines patient-derived ex vivo models, high-content imaging, and deep learning to generate systems-level biological insights, which it applies through strategic partnerships with biopharma companies and an internal therapeutic pipeline. Founded in 2019 and incubated at J&J JLABS, LynxBio is led by an experienced team and has appointed a Chief Business Officer with a strong track record in oncology partnering to drive its commercial strategy and growth.

Proprietary ex vivo disease biology platform integrating patient-derived suspension co-culture assays, automated microfluidics, high-content imaging, orthogonal multi-omic profiling (e.g., genomics, proteomics), and deep learning analytics to generate systems-level insights into tumor-immune interactions.

LynxBio competes in the crowded AI/ML drug discovery sector against companies like Recursion, Exscientia, and Insitro. Its differentiation lies in its specific focus on ex vivo, primary patient-derived models combined with multi-omic integration, with noted expertise in liquid tumors. It also competes with the internal R&D capabilities of large pharmaceutical partners.